Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7E5O

Crystal structure of SARS-CoV-2 RBD in complex with antibody NT-193

Summary for 7E5O
Entry DOI10.2210/pdb7e5o/pdb
DescriptorNT-193 Heavy chain, NT-193 Light chain, Spike protein S1, ... (5 entities in total)
Functional Keywordsspike, igg, viral protein
Biological sourceHomo sapiens
More
Total number of polymer chains3
Total formula weight74064.90
Authors
Primary citationOnodera, T.,Kita, S.,Adachi, Y.,Moriyama, S.,Sato, A.,Nomura, T.,Sakakibara, S.,Inoue, T.,Tadokoro, T.,Anraku, Y.,Yumoto, K.,Tian, C.,Fukuhara, H.,Sasaki, M.,Orba, Y.,Shiwa, N.,Iwata, N.,Nagata, N.,Suzuki, T.,Sasaki, J.,Sekizuka, T.,Tonouchi, K.,Sun, L.,Fukushi, S.,Satofuka, H.,Kazuki, Y.,Oshimura, M.,Kurosaki, T.,Kuroda, M.,Matsuura, Y.,Suzuki, T.,Sawa, H.,Hashiguchi, T.,Maenaka, K.,Takahashi, Y.
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site.
Immunity, 54:2385-, 2021
Cited by
PubMed Abstract: Potent neutralizing SARS-CoV-2 antibodies often target the spike protein receptor-binding site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple sarbecoviruses and drifted viruses. Here, using humanized mice, we identified an RBS antibody with a germline V gene that potently neutralized SARS-related coronaviruses, including SARS-CoV and SARS-CoV-2 variants. X-ray crystallography revealed coordinated recognition by the heavy chain of non-RBS conserved sites and the light chain of RBS with a binding angle mimicking the angiotensin-converting enzyme 2 (ACE2) receptor. The minimum footprints in the hypervariable region of RBS contributed to the breadth of neutralization, which was enhanced by immunoglobulin G3 (IgG3) class switching. The coordinated binding resulted in broad neutralization of SARS-CoV and emerging SARS-CoV-2 variants of concern. Low-dose therapeutic antibody treatment in hamsters reduced the virus titers and morbidity during SARS-CoV-2 challenge. The structural basis for broad neutralizing activity may inform the design of a broad spectrum of therapeutics and vaccines.
PubMed: 34508662
DOI: 10.1016/j.immuni.2021.08.025
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.8 Å)
Structure validation

237423

PDB entries from 2025-06-11

PDB statisticsPDBj update infoContact PDBjnumon